Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$21.5MCash on Hand
26.6mo Cash Runway
Follow LPCN by emailGet an email when LPCN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LPCN, unsubscribe in one click. Privacy
📣 What LPCN Says Is Next
2H 2027 · “Topline results from the BLOOM study are expected in 2H 2027.”
Company press release, Nov 10, 2026 · SEC filing
2H 2027 · Brexanolone: “Topline results from BLOOM study are expected in 2H 2027 SALT LAKE CITY, November 10, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company’s Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD).”
Company press release, Nov 10, 2026 · SEC filing
in 2026 · “Data from this Phase 3 trial are expected to support a 505(b)(2) NDA submission for LPCN 1154 in 2026.”
Company press release, Feb 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Clinical trial Lipocine dosed the first participant in its BLOOM Phase 3 study of LPCN 1154, an oral brexanolone for postpartum depression, with about 120 participants planned and topline results expected in 2H 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings Lipocine reported Q3 2026 net loss of $0.7 million ($0.08 per share), versus $3.2 million a year earlier, on revenue of $2.3 million including $2.1 million in license and collaboration revenue. Cash was $21.5 million at September 30 and about $28.5 million as of November 4, 2026 (unaudited). Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Lipocine updated its corporate presentation for meetings with investors and analysts. The updated presentation is filed as Exhibit 99.1, with no new data disclosed in the filing text. Form 8-K · SEC filing · Press release
Oct 7, 2026 ·
Regulatory Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with male hypogonadism. Licensing partner Verity Pharma plans a Canadian launch by the end of 2026. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Lipocine presented at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14 to 16, 2026 in New York City. The presentation is furnished as Exhibit 99.1, with no new data disclosed in the filing text. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Clinical trial Lipocine announced the start of its approximately 120-participant BLOOM Phase 3 study of LPCN 1154 for postpartum depression, with first dosing expected in early Q4 2026. The prior Phase 3 missed its primary endpoint, and exploratory analyses are not confirmatory. Form 8-K · SEC filing · Press release
Sep 11, 2026 ·
Financing Lipocine and sales agent A.G.P./Alliance Global Partners agreed that the agent's fee on sales under the April 26, 2024 Sales Agreement will be up to 3.0%, subject to adjustment by the parties. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 3 · Recruiting · Brexanolone Lifting Outcomes Of Moms Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not LPCN's own candidates): Testosterone Undecanoate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
LPCN holds $21.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.4M/quarter from operations,
an estimated runway of 26.6 months at that rate (BioRadar estimate, not company guidance).
Share count 11,073,439 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full LPCN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LPCN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.